**Name of Journal:** *World Journal of Dermatology*

**Manuscript NO:** 58408

**Manuscript Type:** LETTER TO THE EDITOR

**Fecal microbiota transplant for more than *Clostridioides difficile*: Dermatology a new frontier**

Snyder AM *et al.* Fecal microbiota transplant for dermatology

Ashley Morgan Snyder, James Abbott, M Kyle Jensen, Aaron M Secrest

**Ashley Morgan Snyder, James Abbott, Aaron M Secrest,** Department of Dermatology, University of Utah, Salt Lake City, UT 84132, United States

**Ashley Morgan Snyder, Aaron M Secrest,** Population Health Sciences, University of Utah, Salt Lake City, UT 84108, United States

**M Kyle Jensen,** Department of Pediatrics, University of Utah, Salt Lake City, UT 84113, United States

**Author contributions:** Snyder AM and Secrest AM coordinated Institutional Review Board approval and data access; Snyder AM, Jensen MK, and Secrest AM provided input in developing methods for the study; Abbott J collected data for this study and addressed the suitability of the data for analysis; Snyder AM drafted the manuscript. All authors were involved in the revision of the manuscript and gave approval for publication.

**Corresponding author: Ashley Morgan Snyder, MPhil, Graduate Assistant,** Department of Dermatology, University of Utah, 30 North 1900 East, 4A330, Salt Lake City, UT 84132, United States. ashley.snyder@utah.edu

**Received:** August 19, 2020

**Revised:** September 16, 2020

**Accepted:** September 22, 2020

**Published online:**

**Abstract**

Fecal microbiota transplant (FMT) has quickly become popular in research not only for recurrent *Clostridioides difficile* infections but for other chronic conditions as well. Recent, small dermatologic studies have reported improvements in inflammatory skin conditions in individuals treated with FMT, but larger studies are needed to clarify this possible relationship between the skin and the gut microbiome. We conducted a single-center, retrospective chart review to assess changes in acne, dermatitis herpetiformis and/or celiac disease, eczema, and psoriasis. Due to the retrospective nature of this study and the limitations of the current electronic medical record, we were unable to adequately assess cases of these diseases in relation to FMT. However, this study informs us that improvements in retrospective data are needed to formally evaluate this possible association. The better, but more cumbersome, study design would be a prospective, observational study. We encourage others to pursue further interdepartmental research on the influence of the gut microbiome on inflammatory skin diseases.

**Key Words:** Fecal microbiota transplantation; Skin diseases; Dermatology; Retrospective; Clostridium difficile; Inflammation

Snyder AM, Abbott J, Jensen MK, Secrest AM. Fecal microbiota transplant for more than *Clostridioides difficile*: Dermatology a new frontier. *World J Dermatol* 2020; In press

**Core Tip:** Future research investigating fecal microbiota transplant’s potential role in treating dermatologic disease needs to focus on large interdisciplinary prospective studies in order to obtain the information needed for determining an association.

**TO THE EDITOR**

Though we wish this letter could provide more answers than questions, we write to you to acknowledge a failure. Evidence has emerged that fecal microbiota transplant (FMT) can influence skin conditions and their treatments, as demonstrated by reports on alopecia universalis[1], psoriasis[2], acne[3], and melanoma immunotherapy[4]. Further, a case report describing a patient with celiac disease whose clinical symptoms disappeared after FMT[5] led to our curiosity in celiac disease and its skin disease cousin, dermatitis herpetiformis. We were thus inspired to conduct a retrospective chart review on all patients who FMT at University of Utah (Institutional Review Board #76927) between January 2013 and December 2019. Our aim was to identify individuals diagnosed with inflammatory skin diseases (acne, dermatitis herpetiformis, eczema, and psoriasis) and/or celiac disease (with or without dermatitis herpetiformis) and look for any evidence of these conditions improving or going into remission after FMT. In total, 141 patients were identified as having undergone FMT (based on ICD-10-CM Diagnosis Code Z94.89), though it appeared only 140 went through with FMT based on what we could find in the electronic medical record. Among those who received FMT, most stool samples were administered via colonoscopy. Some patients received more than one FMT in the time frame of interest, though this did not appear to significantly affect dermatologic outcomes. Our sample included pediatric and adult patients, though most were adult. While 141 patients seemed an adequate number to identify patients for a case series, sadly, none of these individuals had consistent dermatologic data to suggest that FMT might alter gut microbiota sufficiently to impact these conditions.

Why should gastroenterologists who administer FMT care about inflammatory skin diseases? The skin microbiome’s role in dermatologic disease has been given much attention, but the gut microbiome is now entering the spotlight in determining skin disease etiology and potential treatments. The studies previously mentioned stir curiosity as to how inflammatory skin diseases might be affected by the gut microbiome and use of FMT. There is much left to discover about the gut microbiome and how it interacts with other organ systems, but we must expand medical research beyond individual departments to further investigate the subject. Further, at our academic medical center, electronic medical records in their current state lack sufficient clinical information regarding pre- and post-FMT skin issues to explore this relationship rigorously. Future research needs to encourage interdepartmental collaboration and preferably should address the subject using a prospective observational study design.

To conclude, we encourage gastroenterologists administering FMT to assess potential effects FMT can have on their patients’ skin diseases, especially inflammatory processes, and we welcome collaboration on a registry or multicenter cohort study for such work. If your patients develop an inflammatory skin disease or their skin disease changes after FMT, please note this in your charting and/or refer your patients to a dermatologist for follow-up. That FMT you administered may have just cured more than a *Clostridioides difficile* infection.

**REFERENCES**

1 **Rebello D**, Wang E, Yen E, Lio PA, Kelly CR. Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant. *ACG Case Rep J* 2017; **4**: e107 [PMID: 28932754 DOI: 10.14309/crj.2017.107]

2 **Zamudio-Tiburcio1 A,** Bermúdez-Ruiz H, Reyes-López PA. Psoriasis is candidate for intestinal microbiota transplantation? *EC Microbiol* 2019; **15**: 455-460

3 **Borody TJ**, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. *Curr Gastroenterol Rep* 2013; **15**: 337 [PMID: 23852569 DOI: 10.1007/s11894-013-0337-1]

4 **Gopalakrishnan V**, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* 2018; **359**: 97-103 [PMID: 29097493 DOI: 10.1126/science.aan4236]

5 **van Beurden YH**, van Gils T, van Gils NA, Kassam Z, Mulder CJ, Aparicio-Pagés N. Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer. *J Gastrointestin Liver Dis* 2016; **25**: 385-388 [PMID: 27689204 DOI: 10.15403/jgld.2014.1121.253.cel]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflicts-of-interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** August 19, 2020

**First decision:** September 12, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Wang ZK **S-Editor:** Zhang H **L-Editor: P-Editor:**